Responses to Switching to Maraviroc-Based Antiretroviral Therapy in Treated Patients with Suppressed Plasma HIV-1-RNA Load | Zendy

Paola Vitiello | Zendy; Daniel Brudney | Zendy; Malcolm MacCartney | Zendy; Ana Beatriz Garcia | Zendy; Colette Smith | Zendy; Neal Marshall | Zendy; Margaret Johnson | Zendy; Anna María Geretti | Zendy

Open Access

Responses to Switching to Maraviroc-Based Antiretroviral Therapy in Treated Patients with Suppressed Plasma HIV-1-RNA Load

Author(s) -

Paola Vitiello,

Daniel Brudney,

Malcolm MacCartney,

Ana Beatriz Garcia,

Colette Smith,

Neal Marshall,

Margaret Johnson,

Anna María Geretti

Publication year - 2012

Publication title -

intervirology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.641

H-Index - 61

eISSN - 1423-0100

pISSN - 0300-5526

DOI - 10.1159/000332023

Subject(s) - maraviroc , viral load , antiretroviral therapy , virology , human immunodeficiency virus (hiv) , lentivirus , rna , medicine , ccr5 receptor antagonist , immunology , biology , pharmacology , receptor , viral disease , genetics , chemokine , chemokine receptor , gene

Maraviroc (MVC) has shown good efficacy and tolerability in treatment-naive and treatment-experienced HIV-1-infected patients with CCR5-tropic virus. Data on patients switching to MVC while on suppressive antiretroviral therapy (ART) are limited. The aim of this study was to evaluate patients on suppressive ART switching to an MVC-containing regimen (MVC-CR), and test the hypothesis that the switch may have an impact on T cell activation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research